Biotarget最新文献

{"title":"Research progress of long non-coding RNA in ovarian cancer: a narrative review","authors":"Jinxin Qiu, Yanjun Sun, H. Ni, Li Li, Qinghua Xi, Haiyan Jiang","doi":"10.21037/biotarget-22-3","DOIUrl":"https://doi.org/10.21037/biotarget-22-3","url":null,"abstract":"","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49613551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sepsis prognosis related scoring standards: a comprehensive review","authors":"Ruo Wu, Haiyan Jiang, Guomin Mao, Yuting Ren, Yue Wang, Dajun Yan, Zhongwei Huang, Lei Qi, Rongrong Pan","doi":"10.21037/biotarget-21-5","DOIUrl":"https://doi.org/10.21037/biotarget-21-5","url":null,"abstract":"","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44100933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"mRNA vaccine treatment for cancer: a narrative review","authors":"Tianzhen Tang, Sheyu Lin","doi":"10.21037/biotarget-21-8","DOIUrl":"https://doi.org/10.21037/biotarget-21-8","url":null,"abstract":"","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42420734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety for the therapy of liver cancer by combination Sorafenib with other therapies: a literature review","authors":"Qiwen Zhang, Sheyu Lin","doi":"10.21037/biotarget-21-7","DOIUrl":"https://doi.org/10.21037/biotarget-21-7","url":null,"abstract":"Background and Objective: Liver cancer is one of the top ten cancers in the world with new cases occurring in per year. At present, the etiology and exact molecular mechanism of liver cancer are not fully understood. Today, Sorafenib, as a multi-target drug for the treatment of liver cancer in the world, has made obvious progress in many aspects after decades of clinical trials. Many therapeutic regimens have been created and reached a better prognosis which centered on Sorafenib. In order to get a general understanding of sorafenib in therapy for liver cancer, we review the current status of sorafenib solely or in combination with other therapies for liver cancer treatment. Methods: The references in this review are from PubMed, web of science and CBM (China biomedical literature service system) with the key words of Sorafenib, HCC and so on. Most of them are published within ten years and their types include clinical trials, meta-analysis, randomized controlled trials and research articles as well. Key Content and Findings: This article mainly discusses the current situation of clinical application of sorafenib as a targeted drug and the combined therapeutic effect of sorafenib and other therapies, which provides a new way for researchers to improve the clinical efficacy of targeted therapy for liver cancer. Conclusions: Sorafenib, as the first line drug for patients with liver cancer, has significantly improved the patients’ survival by joint or separate way. In the future, more treatment methods may be developed and bring more benefit for liver cancer patients. Of course, some attention should be paid to side effects in patients, including skin redness, hair loss, diarrhea. Lenvatinib, liver neoplasms, and","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44597668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The targets and side effects of CAR-T therapy in the treatment of gastric cancer: a literature review","authors":"Weilong Zhang, Sheyu Lin","doi":"10.21037/biotarget-21-6","DOIUrl":"https://doi.org/10.21037/biotarget-21-6","url":null,"abstract":"","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43338887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A narrative review of the role of m6A in oxidative stress and inflammation","authors":"Zehao Chen, Xin Chen, Yanan Ji, Lilei Zhang, Wei Wang, Yuntian Shen, Hualin Sun","doi":"10.21037/biotarget-21-1","DOIUrl":"https://doi.org/10.21037/biotarget-21-1","url":null,"abstract":"Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, China; Department of Neurology, Affiliated Hospital of Nantong University, Nantong, China Contributions: (I) Conception and design: H Sun; (II) Administrative support: H Sun; (III) Provision of study materials or patients: Z Chen, X Chen, W Wang, L Zhang, Y Ji, Y Shen; (IV) Collection and assembly of data: Z Chen, X Chen, W Wang, L Zhang, Y Ji, Y Shen; (V) Data analysis and interpretation: X Chen, Z Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. These two authors contributed equally to this work. Correspondence to: Dr. Hualin Sun. 19 Qixiu Road, Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Nantong University, Nantong 226001, China. Email: sunhl@ntu.edu.cn.","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46630575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suppression of the dynamic interaction of estrogen receptor with chromatin is critical for therapeutic ligands to repress ER-mediated transcription activities","authors":"M. Chow, Jingyi Peng, Ying Su, D. Tang","doi":"10.21037/BIOTARGET.2020.01.01","DOIUrl":"https://doi.org/10.21037/BIOTARGET.2020.01.01","url":null,"abstract":"Breast cancer (BC) is the second leading cause of cancer deaths in women with annual new cases and fatality of 1.7 million and 500,000 respectively (1). Estrogen receptorpositive (ER) BCs constitute 75% of the cases, and contribute to approximately 50% BC fatality (1). ERα plays critical roles in BC progression in part via transactivating Myc, cyclin D1, vascular endothelial growth factor, and other important oncogenic factors (2,3). Targeting ERα remains the standard of care in ER BCs; endocrine therapy (ET) is likely the most successful targeted cancer therapies. Adjuvant tamoxifen decreases mortality and recurrence by 31% and 50% respectively (4,5). The current toolbox of ET includes estrogen biosynthesis inhibitors (aromatase inhibitors, AIs) and therapeutic ligands; the latter consists of selective estrogen modulators (SERMs, like tamoxifen) and fulvestrant, a selective estrogen down-regulator (SERD). Although ET is clearly beneficial and with multiple options, ER BCs remains a major cause of BC mortality because of resistance. While resistance to ET (ETR) is mediated by complex mechanisms, persistent ER signaling under ET is a major attributor to the resistance; loss of ERα was reported in 17–28% of relapse BCs (6-8). The contributions of ERα in relapse BCs underlies multiple rounds of ET using alternative endocrine treatment. For instance, approximately 20% of relapse ER BCs following tamoxifen treatment are sensitive to AI and fulvestrant (9,10) and approximately 40% of recurrent ER BCs have mutations in ERα (11). Collectively, evidence supports an important role of persistent ERα function in ETR development. The above situation also outlines a clear need to more effectively target ERα. Tamoxifen possesses partial agonist activities. In comparison, fulvestrant is a pure antagonist and thus a more potent antiestrogen, which is attributable to its action of inducing ERα degradation. However, the clinical application of fulvestrant is limited because of its poor solubility and intramuscular route of administration (12,13). This status underlies the current interest in developing new SERDs with improved pharmacokinetic properties for oral administration. Several of these SERDs have been developed and entered clinical trials, including GDC-0810 (multicenter phase Ia/ IIa: NCT01823835), AZD9496 (phase I: NCT02248090; an open-label randomized multicenter trial: NCT03236974), RAD1901 (Elacetrant; phase III: NCT03778931; EudraCT 2018-002990-24), GDC-0927 (NCT02316509), and others. To develop effective antiestrogen ligands, a deep understanding of the mechanisms utilized by the current therapeutic ligands will provide a framework to guide this effort. ERα has been extensively investigated (the number of articles listed in PubMed under “estrogen receptor alpha”: n=20,816) following the cloning of human ERα from MCF7 cells in 1986 (14). ERα is a member of the nuclear receptor superfamily; it consists of 6 domains A-F with domain C Editorial Commentar","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48913118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of the CARE guideline as reporting standard in the Biotarget","authors":"","doi":"10.21037/biotarget.2019.10.01","DOIUrl":"https://doi.org/10.21037/biotarget.2019.10.01","url":null,"abstract":"","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45351299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uronic acid pathway metabolites regulate mesenchymal transition and invasiveness in lung adenocarcinoma.","authors":"Yingxin Zhao, A. Brasier","doi":"10.21037/biotarget.2019.09.01","DOIUrl":"https://doi.org/10.21037/biotarget.2019.09.01","url":null,"abstract":"Metastatic transition results in the greatest morbidity and mortality in patients with cancer (1). Metastasis is a step-wise process that results in local extravasation and hematological dissemination of epithelial tumors (1). Local extravasation involves remodeling extracellular matrix (ECM) coupled with cellular invasion, a process promoted by epithelial mesenchymal transition (EMT). EMT is a complex cellular reprogramming event resulting in dissolution of mucosal tight junctions, loss of apical-basal polarity, reorganization of the cytoskeleton promoting motility and secretion of ECM-modifying proteins (2,3). In epithelial tumors, EMT is triggered by its local stromal microenvironment, including inflammatory cytokines, presence of hypoxia and secretion of epithelial growth factors. Understanding the factors controlling EMT in stem-ness, metastatic potential, chemotherapy resistance and how EMT can be modulated to affect cancer metastasis have been the focus of intense investigation.","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/biotarget.2019.09.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45850731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The application of genome editing technology","authors":"Jianwei Zhu, Wenjing Ma, Ziwei Huang, Qiuyu Zhang, Xiaoying Xie, Xiaoming Yang, Hualin Sun","doi":"10.21037/biotarget.2019.08.04","DOIUrl":"https://doi.org/10.21037/biotarget.2019.08.04","url":null,"abstract":"Genome editing technology is currently the most effective tool for accurately manipulating genomes at specific locations. Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regularly interspaced short palindromic repeats associated Cas9 (CRISPR/Cas9) system were used genome editing technologies. Both editing done with ZFNs and TALENs consist of DNA-binding domains which are fused to endonucleases. This is done to enable a broad range of genetic modifications by inducing DNA double-strand breaks (DSB) that stimulate the error-prone Non-Homologous End-Joining (NHEJ) or a homology-directed repair (HDR) at specific genomic locations. Different to ZFNs and TALENs, the CRISPR/Cas system is an RNA-mediated specific recognition process which DSB been introduced after the sgRNA binds to the targeted DNA sequence. The ZFNs, TALENs and CRISPR/Cas9 systems modify these genomic characteristics precisely through these repair mechanisms, and have been successfully used to manipulate the genome in human cells. These genome editing tools can be used to investigate gene function, to explore the genetic mechanisms of a disease, to discover new therapeutic targets, and to develop new disease models. Moreover, these genome editing technologies have a great potential in gene therapy. Here, we review the latest advances in the application of genome editing technology for the study and treatment of genetic diseases [Duchenne muscular dystrophy (DMD), hemophilia], cancers [chimeric antigen receptor T-cell immunotherapy (CAR-T) technology], viral infections [human immunodeficiency virus (HIV), hepatitis B virus (HBV)], bio-agricultures, and microorganisms.","PeriodicalId":92338,"journal":{"name":"Biotarget","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/biotarget.2019.08.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46916464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}